Abstract
We analyzed the expression of deoxycytidine kinase (dCK), UMP/CMP-kinase (UMP/CMP-K), nucleotide diphosphokinase (NDPK-B) and 5'-nucleotidases cN-II, cN-III, cdN and mdN by quantitative polymerase chain reaction at diagnosis in leukemic blasts from 96 patients with acute myeloid leukemia (AML) treated with ara-C. Our results show that high mRNA levels of cN-II and low mRNA levels of cN-III are correlated with a worse clinical outcome and suggest that these enzymes may have a role in sensitivity to ara-C in AML patients.
MeSH terms
-
5'-Nucleotidase / biosynthesis
-
5'-Nucleotidase / genetics*
-
Acute Disease
-
Adult
-
Aged
-
Antimetabolites, Antineoplastic / administration & dosage
-
Antimetabolites, Antineoplastic / pharmacokinetics*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Bone Marrow Cells / enzymology
-
Cytarabine / administration & dosage
-
Cytarabine / pharmacokinetics*
-
Drug Resistance, Neoplasm / genetics
-
Female
-
Glycoproteins / biosynthesis
-
Glycoproteins / genetics*
-
Humans
-
Leukemia, Myeloid / drug therapy
-
Leukemia, Myeloid / enzymology*
-
Leukemia, Myeloid / genetics
-
Leukemia, Myeloid / mortality
-
Male
-
Middle Aged
-
Neoplasm Proteins / biosynthesis
-
Neoplasm Proteins / genetics*
-
Neoplastic Stem Cells / enzymology*
-
Prognosis
-
Proportional Hazards Models
-
Pyrimidine Nucleotides / metabolism
-
RNA, Messenger / analysis*
-
RNA, Messenger / blood
-
RNA, Neoplasm / analysis*
-
RNA, Neoplasm / blood
-
Reverse Transcriptase Polymerase Chain Reaction
-
Survival Analysis
-
Treatment Outcome
Substances
-
Antimetabolites, Antineoplastic
-
Glycoproteins
-
Neoplasm Proteins
-
Pyrimidine Nucleotides
-
RNA, Messenger
-
RNA, Neoplasm
-
Cytarabine
-
5'-Nucleotidase
-
NT5C2 protein, human
-
NT5C3A protein, human